Biosense Webster
Study: Biosense Webster’s force-sensing catheters lower AF recurrence
J&J’s Biosense Webster wins PMA nod from FDA for force-sensing catheter
Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster subsidiary said it won pre-market approval from the FDA for its ThermoCool SmartTouch force-sensing ablation catheter, making it the 1st such device to hit the U.S. market.
Legal news: J&J’s Biosense Webster can’t keep ex-reps from selling for St. Jude
Biosense Webster launches Afib ablation study for nMARQ system
Endosense CEO Keltjens goes to the races with TactiCath Quartz
Jan Keltjens is betting Endosense and its TactiCath technology can compete with 1 of the largest players in cardiac ablation: Johnson & Johnson‘s (NYSE:JNJ) BioSense Webster division.
HRS 2012 Roundup: Cameron Health, Topera Medical and Riata take center stage
GE Healthcare inks co-development deal with J&J’s Biosense Webster
Embryonic stem cells debut in eye treatment in Advanced Cell Tech’s first human trials | Regulatory Roundup
Advanced Cell Technology Inc. (OTC:ACTC) successfully dosed the first patients in clinical trials of stem cell implantation for blinding eye diseases, making it only the second company in the U.S. to win FDA permission to study a therapy derived from embryonic stem cells.
ACTC’s two trials involve implantation of retinal pigment epithelial cells derived from embryonic stem cells into patients with Stargardt’s macular dystrophy and dry age-related macular degeneration.
Study another positive sign for catheter ablation advocates
Medical device manufacturers seeking regulatory clearances to expand catheter ablation as a treatment for atrial fibrillation got a boost from a new study published in the Journal of the American Medical Assn.
The 19-center study compared the effectiveness of ablation procedures to one of five different drug therapies in treating irregular heartbeats. It found that 70 of the 106 patients, or 66 percent, receiving ablation procedures remained symptom-free a year later, versus only 10 of 61, or 16 percent, of patients treated with arrythymia drugs. All 167 patients participating in study had previously tried at least one drug to control fibrillatons.